Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4 SUPPL. 2, 2003, Pages

  Witters, Lois M ^a   Crispino, Jamie ^a   Fraterrigo, Terri ^b   Green, Jonathan ^c   Lipton, Allan ^a,d  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; COX 2 inhibitor; Docetaxel; HER 2 neu; Zoledronic acid

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIPHOSPHONATES; GENES, ERBB-2; HUMANS; IMIDAZOLES; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; TAXOIDS; TRANSFECTION;

EID: 0043075946     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308002-00011     Document Type: Conference Paper

References (47)

1. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-34.
2. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96.
3. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91: 333-8.
4. Williams CS, Watson AJM, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-51.
5. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-9.
6. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
7. DuBois RN, Awad J, Morrow J, et al. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Investig 1994;93:493-8.
8. Mestre JR, Subbaramaiah K, Sacks PG, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997; 57:2890-5.
9. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637-45.
10. Subbaramaiah K, Chung WJ, Tanabe T, et al. Increased expression of cyclooxygenase-2 in human mammary epithelial cells transformed by the HE2/neu oncogene [Abstract 658]. In: Proceedings of the American Association of Cancer Research Meetings, Philadelphia: American Association for Cancer Research; 1999.
11. Dannenberg AJ, Altorki NK, Subbaramaiah K. Selective inhibitors of COX-2: new applications in oncology. In: Perry MC, ed. American Society of Clinical Oncology Education Book. Alexandria, VA: American Society of Clinical Oncology, 2001:21-27.
12. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
13. Hsueh C-T, Kelsen GK, Schwartz GK. Selective inhibition of cyclooxygenase-2 (COX-2) enhances chemotherapy-induced apoptosis [Abstract 606]. In: Proceedings of the American Society of Clinical Oncology Meetings, Alexandria: American Association of Clinical Oncology; 1999.
14. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-55.
15. Rimarchin JA, Jacobson JA, Szabo P, et al. Regulation of cyclooxygenase-2 in aortic smooth muscle cells. Arterioscler Thromb 1994;14:1021-31.
16. Li M, Wu X, Xu X-C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 2001;7:1010-6.
17. Gschaidmeier H, Faerber L, Schloesser A, et al. Zoledronic acid, a highly potent bisphosphonate compound, exhibits antiangiogenic properties that may confer additional benefit in the treatment of patients with osteolytic bone metastases. Ann Oncol 2000;11(suppl 4):10-11.
18. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
19. Muller K, Wiesenberg I, Jaeggi KA, et al. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat. Drug Res 1998;48:81-6.
20. Binkley N, Kimmel D, Bruner J, et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998;11:1775-82.
21. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid, a potent inhibitor of bone resorption [Abstract #3166]. In: Proceedings from the American Association of Cancer Research, 2001.
22. Benford HL, Helfrich MH, Sebti S, et al. Inhibition of protein geranylgeranylation and GGTI298 causes activation of caspase 3-like proteases in osteoclasts. Calcif Tissue Int 1999;64(suppl 1):S45.
23. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cells. Br J Cancer 2000;82: 1459-68.
24. Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-4.
25. Lee MV, Fong EM, Singer FR, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61: 2602-8.
26. Fromigue O, Lagneaux L, Body J-L. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-21.
27. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
28. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-8.
29. Ringel I, Horwitz SB. Studies with RPR 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91.
30. Diaz JF, Andreau JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-55.
31. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
32. Gumerlock PH, Mack PC, Manorek GH, et al. P27 induction as a potential p53-independent mechanism of apoptotic response to taxanes in non-small cell lung cancer (NSCLC) [Abstract 723]. In: Proceedings of the American Society of Clinical Oncology, Alexandria: American Association of Clinical Oncology; 1999.
33. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495-505.
34. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999;17:2341-54.
35. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-24.
36. Burris AB. Docetaxel (Taxotere) in HER-2 positive patients and in combination with Trastuzumab (Herceptin). Semin Oncol 2000;27: 19-23.
37. HER2 signal transduction in breast cancer cells. J Biol Chem 1991;266:14300-5.
38. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/ neu oncogene. Science 1987;235:177-82.
39. Van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
40. Slamon DJ, Godolphin W, Jones LA, et al. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
41. Press MF, Jones LA, Godolphin W, et al. HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res 1990;354A:209-21.
42. Witters LM, Santala SM, Leitzel KE, et al. Decreased response to paclitaxel versus docetaxel in a HER-2/neu transfected cell line [Abstract 575]. San Antonio Breast Cancer Conference, Hingham: Kluwer Academic Publishers; 2000.
43. Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999;18:305-14.
44. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6: 4932-8.
45. Zhang L, Lau Y-K, Xia W, et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Cancer Res 1999;5:343-53.
46. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
47. Hengstler JG, Lange J, Kett A, et al. Contribution of c-erbB-2 and topoisomerase II to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14.